PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Medicine, University of Missouri, Columbia, MO, United States.\', \'Molecular Pathogenesis and Therapeutics Program, University of Missouri, Columbia, MO, United States.\', \'Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, MO, United States.\', \'Department of Surgery, University of Missouri, Columbia, MO, United States.\', \'School of Medicine, Biomedical Biological, and Chemical Engineering, University of Missouri, Columbia, MO, United States.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.3389/fimmu.2021.714833
?:doi
?:hasPublicationType
?:journal
  • Frontiers in immunology
is ?:pmid of
?:pmid
?:pmid
  • 34745093
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.803
?:rankingScore_hIndex
  • 69
is ?:relation_isRelatedTo_publication of
?:title
  • Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34745093>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34745093>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all